All In MedTech

FDA Clearance Tracker · P210036

PerClot® Polysaccharide Hemostatic System

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: May 19, 2023 (this decision)Source: openFDAMethods & limitations

PMA

Decided

May 19, 2023

Approved

Time to decision

571 days

Received Oct 25, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P210036
Device name
PerClot® Polysaccharide Hemostatic System
Applicant location
Round Lake, IL
Received
Oct 25, 2021
Decided
May 19, 2023
Decision
Approved
Supplements
8 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Regulation
21 CFR 878.4490

Every decision under product code LMG

FDA's approval statement

As written in FDA's record.

Approval for the PerClot® Absorbable Hemostatic Powder. The device is indicated in surgical procedures (except neurological and ophthalmic) as an adjunctive hemostatic device to assist when control of suture line bleeding or capillary, venous and arteriolar bleeding by pressure, ligature, and other conventional procedures is ineffective or impractical.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code LMG. The earliest in FDA's data is N12159, decided Oct 14, 1960.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Baxter Healthcare Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.